Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2023-07-05 00:00:00 ET · period of report 2023-06-30 · accession 0000929638-23-001943 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-07-05 | 2023-06-30 | MLTX | Chen Bihua | 10% | P - Purchase | $50.00 | +800.0K | 4.93M | +19% | +$40.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Shares | 2023-06-30 | P | A | 800,000 | $50.00 | 4,927,100 | I See Footnotes | — | — | (F2) Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly. |